Zemprocitinib

Zemprocitinib
Clinical data
Other names	EQ-121; LNK-01001; LNK-207
Legal status
Legal status	investigational;
Identifiers
	IUPAC name N-[3-(3,5,8,10-tetrazatricyclo[7.3.0.02,6]dodeca-1,4,6,8,11-pentaen-3-yl)-1-bicyclo[1.1.1]pentanyl]propane-1-sulfonamide;
CAS Number	2417414-44-7;
PubChem CID	152231544;
IUPHAR/BPS	13221;
DrugBank	DB21719;
ChemSpider	129380266;
UNII	LG6MM3RP86;
ChEBI	CHEBI:759957;
ChEMBL	ChEMBL6068039;
Chemical and physical data
Formula	C16H19N5O2S
Molar mass	345.42 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CCCS(=O)(=O)NC12CC(C1)(C2)N3C=NC4=CN=C5C(=C43)C=CN5;
	InChI InChI=InChI=1S/C16H19N5O2S/c1-2-5-24(22,23)20-15-7-16(8-15,9-15)21-10-19-12-6-18-14-11(13(12)21)3-4-17-14/h3-4,6,10,20H,2,5,7-9H2,1H3,(H,17,18); Key:WBKCMWRKRQABQF-UHFFFAOYSA-N;

Zemprocitinib is an investigational new drug that is be evaluated by Lynk Pharmaceuticals for the treatment of ankylosing spondylitis and rheumatoid arthritis.^[1] It is an janus kinase 1 (JAK1) inhibitor.^[2]^[3]

Clinical trials

It is currently being evaluated in a phase 3 trials trial for the treatment of rheumatoid rthritis.^[4]

↑ "Zemprocitinib - Lynk Pharmaceuticals". AdisInsight. Springer Nature Switzerland AG.
↑ Cao J, Huang R, Chen Y, Li X, Lou J, Xu L, et al. (2026). "Application of JAK inhibitors in the treatment of rheumatoid arthritis: a systematic analysis based on clinical trial databases and registries". Frontiers in Medicine. 13 1680115. Lausanne. doi:10.3389/fmed.2026.1680115. PMC 12999776. PMID 41868221.
↑ Kubyshkin V, Mykhailiuk PK (March 2026). "Smallest Bicycles in Medicinal Chemistry: Where Are We Now?". Chemical Reviews. 126 (6): 3829–3882. doi:10.1021/acs.chemrev.5c00779. PMID 41818297.
↑ Clinical trial number NCT06276998 for "A Study of LNK01001 Capsule in Subjects With Active Rheumatoid Arthritis (COURAGE-RA) " at ClinicalTrials.gov

This pharmacology-related article is a stub. You can help Wikipedia by adding missing information.